Research programme: microbiome targeted therapeutics - SymberixAlternative Names: Bacterial enzyme inhibitors - Symberix
Latest Information Update: 02 Dec 2015
At a glance
- Originator Symberix
- Class Small molecules
- Mechanism of Action Bacterial protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders
Most Recent Events
- 20 Nov 2015 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)